The company's allogeneic iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development, and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T cell therapies.

The company's lead program is CNTY-101, a CD19-targeting iNK cell therapy. In April 2024, Century announced the an expansion of the drug's clinical development into additional autoimmune disease indications.

As of Q2 2023, CNTY-101 is being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned clinical trial in systemic lupus erythematosus (SLE) (CALiPSO-1).